Maggie is an editor for The American Journal of Managed Care® (AJMC®) and produces written, video, and podcast content covering several disease states. She joined AJMC® in 2019, and has been with AJMC®’s parent company, MJH Life Sciences®, since 2014, when she started as a copy editor.
She has a BA in English from Penn State University. You can connect with Maggie on LinkedIn.
Navigating the Mental Health Challenges of Cancer Diagnosis, Treatment, and Survivorship
March 12th 2024Stress has potential links to worse outcomes in cancer, such as decreased quality of life and greater risks of disease progression and metastasis. There is a complex mix of emotions patients with cancer experience.
Read More
SABR Likely Safe, Effective for Patients Who Have NSCLC, ILD
March 12th 2024In this study, the 42-patient population was enrolled from 5 sites in Canada and 1 site in Scotland, and data were gathered from March 7, 2019, to January 12, 2022; all had interstitial lung disease (ILD) and early-stage non–small cell lung cancer (NSCLC).
Read More
Case Report Warns of Pneumothorax Risk in Duchenne Muscular Dystrophy
March 6th 2024The authors of this report stress the importance of awareness of COVID-19–related complications in young patients who have Duchenne muscular dystrophy, paying particular attention to a potential higher risk of respiratory infections in these patients.
Read More
Dr Joshua Sabari Discusses Amivantamab’s First-Line Approval for NSCLC
March 4th 2024The approval converts the May 2021 accelerated FDA approval for second-line treatment of non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations to a full approval in the first line following results from the phase 3 PAPILLON study.
Read More
Optimizing CAR T for Patients With BCL and CNS Involvement
February 29th 2024With little data available on outcomes among patients who have B-cell lymphoma (BCL) and secondary central nervous system (CNS) involvement who were administered CD19-targeting chimeric antigen receptor (CAR) T-cell therapy, these investigators enrolled 4 male patients in their study.
Read More
Smartphone Tech Reveals Gait Differences in Duchenne Muscular Dystrophy
February 28th 2024Outside of a gait laboratory, this investigation compared gait pattern differences between children who have Duchenne muscular dystrophy (DMD) and their typically developing counterparts to gain more real-world data of DMD-associated gait characteristics.
Read More
Nivolumab Continues to Produce Beneficial NSCLC Outcomes
February 27th 2024This most recent analysis from the CheckMate 9LA trial provides 4-year follow-up data on patients with stage IV metastatic/recurrent non–small cell lung cancer (NSCLC) randomized to treatment with nivolumab plus ipilimumab and chemotherapy vs chemotherapy alone.
Read More
Getting to Know Dr Fabiola Molina, Hospitalist
February 26th 2024Fabiola Molina, MD, MHS, is a practicing hospitalist and assistant professor of medicine at Yale School of Medicine and Yale New Haven Hospital. An immigrant from Mexico, her experiences straddling 2 worlds, while attempting to navigate with her family the complicated safety-net system for health care in Texas, were key influences to her ardent focus on health equity.
Read More
Part 4: Dr James Robinson on the Impact of 340B Programs and Drug Pricing Policies
February 26th 2024In this final part of our interview with James Robinson, PhD, MPH, he underscores the need for employer education about the health plans they offer, fostering managed competition among hospital systems to drive down costs, and innovation in financing drug development.
Read More
Part 3: Dr James Robinson on the Impact of 340B Programs and Drug Pricing Policies
February 23rd 2024In part 3 of our interview with James Robinson, PhD, MPH, he discusses the need for reforms to commercial insurance that reflect the changes to Medicare under the Inflation Reduction Act, how the 340B drug pricing program has veered widely from its original goals, and ongoing cost sharing struggles among patients, insurers, hospitals, and drug companies.
Read More
Getting to Know Dr Shauna Downs, Public Health Nutritionist
February 23rd 2024Shauna Downs, PhD, MS, is an associate professor in the Department of Health Behavior, Society, and Policy at the Rutgers School of Public Health. A former figure skater, her research now focuses on interventions to promote healthy and sustainable food choices and exploring how our changing climate, food systems, diet, and nutrition are inextricably linked.
Read More
For chimeric antigen receptor T-cell therapies (CAR T) approved to treat B-cell lymphoproliferative disorders and multiple myeloma, more data are needed on the effects of posttreatment myeloid neoplasms to optimize patient counseling, risk stratification, and surveillance.
Read More
Part 2: Dr James Robinson on the Impact of 340B Programs and Drug Pricing Policies
February 20th 2024In part 2 of our interview with Robinson, he addresses the potential for exacerbated health care disparities in the aftermath of hospital price markups and how insurance plan design often disadvantages the patients who most need expensive infusion therapies but cannot afford them.
Read More
Getting to Know Dr Doug Marks, Oncology Clinical Trialist
February 20th 2024Douglas K. Marks, MD, is a breast medical oncologist and director of the Clinical Trials Office, Perlmutter Cancer Center, NYU Langone Hospital—Long Island, as well as associate professor in the Department of Medicine at NYU Grossman Long Island School of Medicine. As a phase 1 clinical trialist, he sees both patients with breast cancer and those who are looking to receive innovative treatments for their early-stage disease.
Read More
Part 1: Dr James Robinson on the Impact of 340B Programs and Drug Pricing Policies
February 16th 2024In the January issue of The New England Journal of Medicine, James Robinson, PhD, MPH, and his fellow investigators published their findings from an analysis of how insurer drug expenditures on infused drugs influenced price markups at hospitals.
Read More
Daratumumab-Based Regimen Potential Promising Bridging Therapy for RRMM
February 15th 2024The combination of daratumumab and immumodulatory therapy was evaluated among patients with relapsed/refractory multiple myeloma (RRMM) who have failed prior treatment with immunomodulatory agents, proteasome inhibitors, and daratumumab as monotherapy or in combination.
Read More
In Adolescents With Obesity, FMT Shows No Negative Impact on Horizontal Gene Transfer
February 15th 2024For this analysis, investigators used metagenomic sequencing files from the Gut Bugs trial, a placebo-controlled multidonor fecal microbiota transplantation (FMT) trial conducted among adolescents classified as obese.
Read More
Durvalumab Consolidation Therapy Shows Promise in Elderly Patients With Stage III NSCLC
February 12th 2024Consolidation durvalumab led to comparable outcomes among older patients with unresectable stage III non–small cell lung cancer (NSCLC) vs a younger cohort with the same cancer; this patient population was underrepresented in the PACIFIC trial.
Read More
Dr Chandler Cortina: In Oncology, We Treat the Disease and the Person
February 12th 2024In this interview, Chandler Cortina, MD, MS, FSSO, FACS, Froedtert & the Medical College of Wisconsin, addresses the impact that prioritizing mental health care can have on patients as they navigate through their cancer journey.
Read More
In-House Biomarker Testing Shortens Time to Treatment Decision for mNSCLC
February 9th 2024This retrospective analysis compared molecular testing outcomes among newly diagnosed cases of metastatic non–small cell lung cancer (mNSCLC) from 2 periods: March 2017 to May 2019 and July 2019 to March 2021.
Read More
Getting to Know Dr Chandler Cortina, Breast Surgical Oncologist
February 9th 2024Chandler Cortina, MD, MS, FSSO, FACS, is assistant professor of surgery and breast surgical oncologist at Froedtert & the Medical College of Wisconsin. His current research focuses on breast cancer risk not only in general but also among transgender and gender-diverse populations.
Read More
COA's Dr Miriam Atkins: PBMs, HR 5526, and Marketplace Strategy
February 7th 2024Miriam J. Atkins, MD, FACP, president of the Community Oncology Alliance, discusses the impact of pharmacy benefit managers (PBMs) on health care costs and offers potential ways to remedy certain CMS decisions that negatively affect oncologists and their patients.
Read More